Close Menu

More articles about Gastrointestinal

Genes and pathways related to mesenchymal biology, connective tissue, and conditions like obesity came to the forefront when researchers analyzed the new susceptibility loci.

Genome-wide association study hits can uncover potential therapies for conditions like inflammatory bowel disease, a Biology of Genomes speaker said.

Diversigen will act as a central lab for generating and incorporating microbiome data into the Crohn's & Colitis Foundation's IBD Plexus platform.

The company said it will use the proceeds to accelerate development of its gastrointestinal platform, including diagnostics and therapeutics for the GI tract.

The firm said that a number of hospitals and labs are expected to evaluate the panel, presenting it with about a $2.0 million annual revenue opportunity.  

The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.

The firm's treatments are based on stimulating the innate immune system with drugs made from inactivated bacteria to restore normal immune function.

The model incorporates clinical, serological, and gene expression factors, and could be used to tailor treatment choices.

The firm's GI panel has also been recently evaluated in pediatric populations, demonstrating a marked increase in overall pathogen detection.

Nearly 8,000 patients participated in a screening study that used a PCR-based detection assay from Becton Dickinson, uncovering a 5 percent carrier rate.

On an organic basis, Q1 revenues grew more than 11 percent, driven in part by strong sales of its FilmArray, Vidas, and Vitek product portfolios.

The high-throughput system is now approved with the firm's Blood Culture ID, Gastrointestinal, Meningitis/Encephalitis, and the previously approved Respiratory Panel. 

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.